基于数据挖掘分析FAM134B在肝癌中的表达及其与预后的关系

钟蓝海; 马丹丹; 张智勇; 张翌; 蔡逊

doi:10.3969/j.issn.1001-5256.2019.11.023

基于数据挖掘分析FAM134B在肝癌中的表达及其与预后的关系

DOI: 10.3969/j.issn.1001-5256.2019.11.023

1. 南方医科大学第一临床医学院
2. 中国人民解放军中部战区总医院普通外科

基金项目:

湖北省卫生健康委科研联合项目(WJ2019H104)；湖北省自然科学基金资助项目(2012FFB06805)；

详细信息

中图分类号: R735.7;TP311.13
计量
- 文章访问数: 1270
- HTML全文浏览量: 25
- PDF下载量: 265
- 被引次数: 0
出版历程
- 收稿日期: 2019-06-18
- 出版日期: 2019-11-20

Expression of FAM134B in liver cancer and its association with prognosis: An analysis based on data mining

The First Clinical Medical College of Southern Medical University

Research funding:

摘要

摘要: 目的研究FAM134B在肝癌组织中的表达情况,探讨其表达差异与临床病理特征以及预后生存的关系。方法挖掘Oncomine、Human Protein Atlas、TCGA和Kaplan Meier-Plotter数据库,分析FAM134B在肝癌组织中的表达,并对表达量与临床病理特征以及预后生存的关系进行探讨。计数资料组间比较采用χ2检验。FAM134B表达与肝癌预后的关系采用Kaplan-Meier模型分析。结果正常组织中,FAM134B在肾脏中表达量最高,肝脏居第9位,肿瘤组织中,其在肾癌组织表达最高,肝癌第11位。共147项有关FAM134B表达差异的研究结果差异具有统计学意义,各种癌症中其表达差异不一致。其在肝癌组织中表达量较正常肝组织中低。FAM134B蛋白定位于内质网,其表达量与肝癌患者发病年龄、肝硬化、AFP、人种、分化程度有相关性（P值均<0. 05）。FAM134B表达量与肝癌患者总生存率有关[风险比（HR）=0. 67,95%可信区间（95%CI）:0. 47～0. 95,P=0. 026],且对亚洲人种预后有显著影响（HR=0. 40,95...
- 肝肿瘤 /
- 数据挖掘 /
- FAM134B /
- 预后
Abstract: Objective To investigate the expression of FAM134 B in liver cancer and its association with clinicopathological features and prognosis. Methods Data mining was performed for Oncomine,Human Protein Atlas,TCGA,and Kaplan Meier-Plotter databases to analyze the expression of FAM134 B in liver cancer,and the association of the expression of FAM134 B with clinicopathological characteristics and prognosis was analyzed. The chi-square test was used for comparison of categorical data between groups,and the Kaplan-Meier method was used to investigate the association between FAM134 B expression and prognosis of liver cancer. Results As for normal tissue,the highest expression level of FAM134 B was found in the kidney,and the expression of FAM134 B in the liver ranked 9 th; as for tumor tissue,the highest expression of FAM134 B was found in renal cancer,and the expression of FAM134 B in liver cancer ranked 11 th. A total of 147 studies found a significant difference in FAM134 B expression,and there was a significant difference in FAM134 B expression between various tumors. FAM134 B expression in liver cancer tissue was lower than that in normal liver tissue. FAM134 B protein was localized in the endoplasmic reticulum,and its expression was associated with age of onset of liver cancer patients,liver cirrhosis,alpha-fetoprotein,race,and degree of tumor differentiation( all P < 0. 05). FAM134 B expression was associated with the overall survival rate of liver cancer patients( hazard ratio [HR]= 0. 67,95% confidence interval[CI]: 0. 47-0. 95,P = 0. 026) and had significant influence on the prognosis of the Asian population( HR = 0. 40,95% CI: 0. 22-0. 74,P = 0. 003),while it had no significant influence on the prognosis of the Caucasian population( HR = 0. 65,95% CI: 0. 40-1. 05,P = 0. 076). Conclusion There is a significant difference in the expression of FAM134 B between tumors,with a low expression in liver cancer. FAM134 B protein is localized in the endoplasmic reticulum,and its low expression is associated with several malignant phenotypes of liver cancer and the low overall survival rate.
- liver neoplasms /
- data mining /
- family with sequence similarity 96,member B /
- prognosis

HTML全文

参考文献(28)

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global Cancer Statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.

[2] Chinese Society of Liver Cancer,Chinese Medical Doctor Association. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus(2018)[J]. J Clin Hepatol,2019,35(4):737-743.(in Chinese)中国医师协会肝癌专业委员会．肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2018年版)[J]．临床肝胆病杂志，2019,35(4):737-743.

[3] SENGUPTA S,PARIKH ND. Biomarker development for hepatocellular carcinoma early detection:Current and future perspectives[J]. Hepat Oncol,2017,4(4):111-122.

[4] HUANG XJ,ZHANG WX. Expression features and clinical significance of the microRNA-888 gene family in hepatocellular carcinoma[J]. J Clin Hepatol,2019,35(1):119-122.(in Chinese)黄湘俊，张文兴．肝细胞癌中microRNA-888基因家族的表达特征及临床意义[J]．临床肝胆病杂志，2019,35(1):119-122.

[5] WAHL DR,STENMARK MH,TAO Y,et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma[J]. J Clin Oncol,2016,34(5):452-459.

[6] KHAMINETS A,HEINRICH T,MARI M,et al. Regulation of endoplasmic reticulum turnover by selective autophagy[J].Nature,2015,522(7556):354-358.

[7] WURMBACH E,CHEN YB,KHITROV G,et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma[J]. Hepatology,2007,45(4):938-947.

[8] CHEN K,MANGA P,ORLOW SJ. Pink-eyed dilution protein controls the processing of tyrosinase[J] Mol Biol Cell,2002,13(6):1953-1964.

[9] ROESSLER S,JIA HL,BUDHU A,et al. A unique metastasis gene signature enables prediction of tumor relapse in earlystage hepatocellular carcinoma patients[J]. Cancer Res,2010,70(24):10202-10212.

[10] MAS VR,MALUF DG,ARCHER KJ,et al. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma[J]. Mol Med,2009,15(3-4):85-94.

[11] FANG CY,ZHU CW,ZHANG QS,et al. Expression and clinical significance of long non-coding RNA exocyst complex component 7 in hepatocellular carcinoma[J]. J Clin Hepatol,2019,35(1):123-126.(in Chinese)方长英，朱传卫，张青松，等．原发性肝癌组织中长链非编码RNA外泌体复合物7的表达及临床意义[J]．临床肝胆病杂志，2019,35(1):123-126.

[12] CHEN WY,REN N. Advances in molecular targeted therapy for hepatocellular carcinoma[J]. J Clin Hepatol,2018,34(7):1387-1394.(in Chinese)陈万勇，任宁．肝细胞癌分子靶向治疗进展[J]．临床肝胆病杂志，2018,34(7):1387-1394.

[13] LEI GL,WANG Q,CHENG SJ,et al. Expression of the long non-coding RNA XLOC-007123 in hepatitis B-related hepatocellular carcinoma and its clinical significance[J]. J Clin Hepatol,2018,34(2):309-313.(in Chinese)雷光林，王权，程思杰，等．长链非编码RNA XLOC-007123在乙型肝炎相关肝细胞癌中的表达及临床意义[J]．临床肝胆病杂志，2018,34(2):309-313.

[14] MIZUSHIMA N,KOMATSU M. Autophagy:Renovation of cells and tissues[J]. Cell,2011,147(4):728-741.

[15] KLIONSKY DJ. Autophagy revisited:A conversation with Christian de Duve[J]. Autophagy,2008,4(6):740-743.

[16] RUBINSZTEIN DC. Cell biology:Receptors for selective recycling[J]. Nature,2015,522(7556):291-292.

[17] ISLAM F,GOPALAN V,LAM AK. RETREG1(FAM134B):A new player in human diseases:15 years after the discovery in cancer[J]. J Cell Physiol,2018,233(6):4479-4489.

[18] BERNALES S,McDONALD KL,WALTER P. Autophagy counterbalances endoplasmic reticulum expansion during the unfolded protein response[J]. PLo S Biol,2006,4(12):e423.

[19] KONG M,KIM Y,LEE C. A strong synergistic epistasis between FAM134B and TNFRSF19 on the susceptibility to vascular dementia[J]. Psychiatr Genet,2011,21(1):37-41.

[20] LENNEMANN NJ,COYNE CB. Dengue and Zika viruses subvert reticulophagy by NS2B3-mediated cleavage of FAM134B[J]. Autophagy,2017,13(2):322-332.

[21] CHIRAMEL AI,DOUGHERTY JD,NAIR V,et al. FAM134B,the selective autophagy receptor for endoplasmic reticulum turnover,inhibits replication of ebola virus strains makona and mayinga[J]. J Infect Dis,2016,214(Suppl 3):s319-s325.

[22] MELCHIOTTI R,PUAN KJ,ANDIAPPAN AK,et al. Genetic analysis of an allergic rhinitis cohort reveals an intercellular epistasis between FAM134B and CD39[J]. BMC Med Genet,2014,15:73.

[23] RIVIERE JB,RAMALINGAM S,LAVASTRE V,et al. KIF1A,an axonal transporter of synaptic vesicles,is mutated in hereditary sensory and autonomic neuropathy type 2[J]. Am J Hum Genet,2011,89(2):219-230.

[24] MURPHY SM,DAVIDSON GL,BRANDNER S,et al. Mutation in FAM134B causing severe hereditary sensory neuropathy[J]. J Neurol Neurosurg Psychiatry,2012,83(1):119-120.

[25] ILGAZ AYDINLAR E,ROLFS A,SERTESER M,et al. Mutation in FAM134B causing hereditary sensory neuropathy with spasticity in a Turkish family[J]. Muscle Nerve,2014,49(5):774-775.

[26] DAVIDSON G,MURPHY S,POLKE J,et al. Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort[J]. J Neurol,2012,259(8):1673-1685.

[27] KASEM K,GOPALAN V,SALAJEGHEH A,et al. JK1(FAM134B)gene and colorectal cancer:A pilot study on the gene copy number alterations and correlations with clinicopathological parameters[J]. Exp Mol Pathol,2014,97(1):31-36.

[28] TANG WK,CHUI CH,FATIMA S,et al. Oncogenic properties of a novel gene JK-1 located in chromosome 5p and its overexpression in human esophageal squamous cell carcinoma[J]. Int J Mol Med,2007,19(6):915-923.

施引文献

资源附件(0)

访问统计